Open Access

mAbs, volume 13, issue 1

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro

Haolin Liu ^{1, 2}

PENGCHENG WEI ^{1, 2}

Qianqian Zhang ³

Zhongzhou Chen ³

Katja Aviszus ^{1, 2}

Walter DOWNING ⁴

Shelley Peterson ⁴

Lyndon Reynoso ⁵

Gregory P. Downey ⁶

Stephen K. Frankel ⁶

Kappler John ^{1, 2}

John W. Kappler ^{1, 2}

Philippa C. Marrack ^{1, 2}

Gongyi Zhang ^{1, 2}

Hide authors affiliations Show authors affiliations: 6 affiliations

Department of Immunology and Microbiology, School of Medicine, Anschutz Medical Center, University of Colorado, Aurora, CO, USA |

Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO, USA |

State Key Laboratory of Agrobiotechnology, College of Biological Sciences, China Agriculture University, Beijing, People’s Republic of China |

⁴

Department of Nursing, National Jewish Health, Denver, CO, USA |

⁵

Department of Pharmacy, National Jewish Health, Denver, CO, USA |

⁶

Department of Medicine, National Jewish Health, Denver, CO, USA |

Publication type: Journal Article

Publication date: 2021-01-01

Taylor & Francis

Journal: mAbs

Quartile SCImago

Quartile WOS

Impact factor: 5.3

ISSN: 19420862, 19420870

DOI: 10.1080/19420862.2021.1919285

Copy DOI

Immunology

Immunology and Allergy

Abstract

The newly emerging variants of SARS-CoV-2 from South Africa (B.1.351/501Y.V2) and Brazil (P.1/501Y.V3) have led to a higher infection rate and reinfection of COVID-19 patients. We found that the mutations K417N, E484K, and N501Y within the receptor-binding domains (RBDs) of the virus could confer ~2-fold higher binding affinity to the human receptor, angiotensin converting enzyme 2 (ACE2), compared to the wildtype RBD. The mutated version of RBD also completely abolishes the binding of bamlanivimab, a therapeutic antibody, in vitro. Detailed analysis shows that the ~10-fold gain of binding affinity between ACE2 and Y501-RBD, which also exits in the high contagious variant B.1.1.7/501Y.V1 from the United Kingdom, is compromised by additional introduction of the K417/N/T mutation. Mutation of E484K leads to the loss of bamlanivimab binding to RBD, although this mutation does not affect the binding between RBD and ACE2.

By date By citations

Top-30

Citations by journals

	1 2
Viruses	Viruses, 2, 4.08% Viruses 2 publications, 4.08%
Pathogens	Pathogens, 2, 4.08% Pathogens 2 publications, 4.08%
Frontiers in Immunology	Frontiers in Immunology, 2, 4.08% Frontiers in Immunology 2 publications, 4.08%
Biomedicines	Biomedicines, 1, 2.04% Biomedicines 1 publication, 2.04%
Health Science Reports	Health Science Reports, 1, 2.04% Health Science Reports 1 publication, 2.04%
Infectious Diseases in Clinical Practice	Infectious Diseases in Clinical Practice, 1, 2.04% Infectious Diseases in Clinical Practice 1 publication, 2.04%
Journal of Personalized Medicine	Journal of Personalized Medicine, 1, 2.04% Journal of Personalized Medicine 1 publication, 2.04%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 1, 2.04% International Journal of Molecular Sciences 1 publication, 2.04%
Frontiers in Medicine	Frontiers in Medicine, 1, 2.04% Frontiers in Medicine 1 publication, 2.04%
Journal of Microbiology	Journal of Microbiology, 1, 2.04% Journal of Microbiology 1 publication, 2.04%
Scientific Reports	Scientific Reports, 1, 2.04% Scientific Reports 1 publication, 2.04%
International Journal for Equity in Health	International Journal for Equity in Health, 1, 2.04% International Journal for Equity in Health 1 publication, 2.04%
Biological Trace Element Research	Biological Trace Element Research, 1, 2.04% Biological Trace Element Research 1 publication, 2.04%
Nature Reviews Microbiology	Nature Reviews Microbiology, 1, 2.04% Nature Reviews Microbiology 1 publication, 2.04%
Journal of Pharmaceutical Analysis	Journal of Pharmaceutical Analysis, 1, 2.04% Journal of Pharmaceutical Analysis 1 publication, 2.04%
Biomedicine and Pharmacotherapy	Biomedicine and Pharmacotherapy, 1, 2.04% Biomedicine and Pharmacotherapy 1 publication, 2.04%
EBioMedicine	EBioMedicine, 1, 2.04% EBioMedicine 1 publication, 2.04%
The Lancet Infectious Diseases	The Lancet Infectious Diseases, 1, 2.04% The Lancet Infectious Diseases 1 publication, 2.04%
American Journal of Pathology	American Journal of Pathology, 1, 2.04% American Journal of Pathology 1 publication, 2.04%
Gene Reports	Gene Reports, 1, 2.04% Gene Reports 1 publication, 2.04%
Expert Opinion on Biological Therapy	Expert Opinion on Biological Therapy, 1, 2.04% Expert Opinion on Biological Therapy 1 publication, 2.04%
Antibody Therapeutics	Antibody Therapeutics, 1, 2.04% Antibody Therapeutics 1 publication, 2.04%
JAMA - Journal of the American Medical Association	JAMA - Journal of the American Medical Association, 1, 2.04% JAMA - Journal of the American Medical Association 1 publication, 2.04%
eLife	eLife, 1, 2.04% eLife 1 publication, 2.04%
Intelligent Systems Reference Library	Intelligent Systems Reference Library, 1, 2.04% Intelligent Systems Reference Library 1 publication, 2.04%
Journal of Molecular Biology	Journal of Molecular Biology, 1, 2.04% Journal of Molecular Biology 1 publication, 2.04%
American Journal of Health-System Pharmacy	American Journal of Health-System Pharmacy, 1, 2.04% American Journal of Health-System Pharmacy 1 publication, 2.04%
Voprosy Virusologii	Voprosy Virusologii, 1, 2.04% Voprosy Virusologii 1 publication, 2.04%
Molecular Neurobiology	Molecular Neurobiology, 1, 2.04% Molecular Neurobiology 1 publication, 2.04%
	1 2

Citations by publishers

	1 2 3 4 5 6 7 8 9
Springer Nature	Springer Nature, 9, 18.37% Springer Nature 9 publications, 18.37%
Multidisciplinary Digital Publishing Institute (MDPI)	Multidisciplinary Digital Publishing Institute (MDPI), 7, 14.29% Multidisciplinary Digital Publishing Institute (MDPI) 7 publications, 14.29%
Elsevier	Elsevier, 7, 14.29% Elsevier 7 publications, 14.29%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 6, 12.24% Cold Spring Harbor Laboratory 6 publications, 12.24%
Frontiers Media S.A.	Frontiers Media S.A., 4, 8.16% Frontiers Media S.A. 4 publications, 8.16%
Oxford University Press	Oxford University Press, 2, 4.08% Oxford University Press 2 publications, 4.08%
Wiley	Wiley, 1, 2.04% Wiley 1 publication, 2.04%
Wolters Kluwer Health	Wolters Kluwer Health, 1, 2.04% Wolters Kluwer Health 1 publication, 2.04%
Han-Gug Misaengmul Hag-hoe/The Microbiological Society of Korea	Han-Gug Misaengmul Hag-hoe/The Microbiological Society of Korea, 1, 2.04% Han-Gug Misaengmul Hag-hoe/The Microbiological Society of Korea 1 publication, 2.04%
Xi'an Jiaotong University	Xi'an Jiaotong University, 1, 2.04% Xi'an Jiaotong University 1 publication, 2.04%
Taylor & Francis	Taylor & Francis, 1, 2.04% Taylor & Francis 1 publication, 2.04%
American Medical Association (AMA)	American Medical Association (AMA), 1, 2.04% American Medical Association (AMA) 1 publication, 2.04%
eLife Sciences Publications	eLife Sciences Publications, 1, 2.04% eLife Sciences Publications 1 publication, 2.04%
American Society of Health-System Pharmacists	American Society of Health-System Pharmacists, 1, 2.04% American Society of Health-System Pharmacists 1 publication, 2.04%
Central Research Institute for Epidemiology	Central Research Institute for Epidemiology, 1, 2.04% Central Research Institute for Epidemiology 1 publication, 2.04%
Royal Society of Chemistry (RSC)	Royal Society of Chemistry (RSC), 1, 2.04% Royal Society of Chemistry (RSC) 1 publication, 2.04%
Bentham Science	Bentham Science, 1, 2.04% Bentham Science 1 publication, 2.04%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii	Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii, 1, 2.04% Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii 1 publication, 2.04%
	1 2 3 4 5 6 7 8 9

We do not take into account publications without a DOI.
Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
Statistics recalculated weekly.

{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2021,2022,2023,2024],"ids":[0,0,0,0],"codes":[0,0,0,0],"imageUrls":["","","",""],"datasets":[{"label":"Citations number","data":[14,21,9,5],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":["28.57","42.86","18.37","10.2"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["Viruses","Pathogens","Frontiers in Immunology","Biomedicines","Health Science Reports","Infectious Diseases in Clinical Practice","Journal of Personalized Medicine","International Journal of Molecular Sciences","Frontiers in Medicine","Journal of Microbiology","Scientific Reports","International Journal for Equity in Health","Biological Trace Element Research","Nature Reviews Microbiology","Journal of Pharmaceutical Analysis","Biomedicine and Pharmacotherapy","EBioMedicine","The Lancet Infectious Diseases","American Journal of Pathology","Gene Reports","Expert Opinion on Biological Therapy","Antibody Therapeutics","JAMA - Journal of the American Medical Association","eLife","Intelligent Systems Reference Library","Journal of Molecular Biology","American Journal of Health-System Pharmacy","Voprosy Virusologii","Molecular Neurobiology"],"ids":[2455,20044,1699,24421,29488,8164,2479,14627,17043,19204,13767,8318,10306,22276,8485,23951,23878,7334,18557,13785,10768,23656,12301,24138,20798,19701,19081,6684,24041],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/6QE8LXWrLpkoy5A2te6hw7who46GeCoTYIstuoAz_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/yNSijlgQghQF53VZuyFLA30CKDe4j3HK74Vtpnxa_medium.webp","\/storage\/images\/resized\/brnEFyEeTGw9nlsHnEHbyCV6AqrisRCX7QF1dLtY_medium.webp","\/storage\/images\/resized\/eIZgkq1MRZyJ3hBkdupnUUv7wgB6zCl9D99SlPN5_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/1m3LXY50cNi8fI7nCBdvoi4rhQMp4gd6vmoowUF7_medium.webp","\/storage\/images\/resized\/HxgFXojL9GSWD86Qe827ZjqG8ciNkkviz42FIGJU_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp"],"datasets":[{"label":"","data":[2,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[4.08,4.08,4.08,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Springer Nature","Multidisciplinary Digital Publishing Institute (MDPI)","Elsevier","Cold Spring Harbor Laboratory","Frontiers Media S.A.","Oxford University Press","Wiley","Wolters Kluwer Health","Han-Gug Misaengmul Hag-hoe\/The Microbiological Society of Korea","Xi'an Jiaotong University","Taylor & Francis","American Medical Association (AMA)","eLife Sciences Publications","American Society of Health-System Pharmacists","Central Research Institute for Epidemiology","Royal Society of Chemistry (RSC)","Bentham Science","Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii"],"ids":[8,202,17,6909,208,19,11,32,5463,2777,18,2676,6627,5437,7217,123,39,9422],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/hg4jJjT8wVGtHstBCc0zk465Mg9pLx3G4odCDOqE_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/yNSijlgQghQF53VZuyFLA30CKDe4j3HK74Vtpnxa_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/6QE8LXWrLpkoy5A2te6hw7who46GeCoTYIstuoAz_medium.webp","","","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/brnEFyEeTGw9nlsHnEHbyCV6AqrisRCX7QF1dLtY_medium.webp","\/storage\/images\/resized\/eIZgkq1MRZyJ3hBkdupnUUv7wgB6zCl9D99SlPN5_medium.webp","\/storage\/images\/resized\/1m3LXY50cNi8fI7nCBdvoi4rhQMp4gd6vmoowUF7_medium.webp","\/storage\/images\/resized\/HxgFXojL9GSWD86Qe827ZjqG8ciNkkviz42FIGJU_medium.webp","\/storage\/images\/resized\/leiAYcRDGTSl5B1eCnwpSGqmDEUEfDPPoYisFGhT_medium.webp","\/storage\/images\/resized\/doUaFUZdxUEQjLi1TwZjGHi8HXYNWWSk04dSC6Xh_medium.webp","\/storage\/images\/resized\/9Mus3KG1Tkd7Bwaurt8H3RwWh0CxRlGoO6ng9UK1_medium.webp"],"datasets":[{"label":"","data":[9,7,7,6,4,2,1,1,1,1,1,1,1,1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[18.37,14.29,14.29,12.24,8.16,4.08,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"yearsCitationsQuartiles":{"type":"bar","data":{"show":true,"labels":[2021,2022,2023,2024],"ids":[],"codes":[],"imageUrls":[],"datasets":[{"label":"Q4","backgroundColor":"rgb(221,90,78)","data":[3,1,0,0],"percentage":["6.12","2.04","0","0"]},{"label":"Q3","backgroundColor":"rgb(251, 163,83)","data":[0,0,0,0],"percentage":["0","0","0","0"]},{"label":"Q2","backgroundColor":"rgb(232, 213, 89)","data":[2,2,1,2],"percentage":["4.08","4.08","2.04","4.08"]},{"label":"Q1","backgroundColor":"rgb(164, 207, 99)","data":[5,15,6,2],"percentage":["10.2","30.61","12.24","4.08"]},{"label":"Quartile not defined","backgroundColor":"#E5E7EB","data":[4,3,2,1],"percentage":["8.16","6.12","4.08","2.04"]}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations quartiles by SCImago per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"yearsCitationsQuartilesWs":{"type":"bar","data":{"show":true,"labels":[2021,2022,2023,2024],"ids":[],"codes":[],"imageUrls":[],"datasets":[{"label":"Q4","backgroundColor":"rgb(221,90,78)","data":[0,0,0,0],"percentage":["0","0","0","0"]},{"label":"Q3","backgroundColor":"rgb(251, 163,83)","data":[1,1,0,1],"percentage":["2.04","2.04","0","2.04"]},{"label":"Q2","backgroundColor":"rgb(232, 213, 89)","data":[3,5,3,1],"percentage":["6.12","10.2","6.12","2.04"]},{"label":"Q1","backgroundColor":"rgb(164, 207, 99)","data":[2,10,3,2],"percentage":["4.08","20.41","6.12","4.08"]},{"label":"Quartile not defined","backgroundColor":"#E5E7EB","data":[8,5,3,1],"percentage":["16.33","10.2","6.12","2.04"]}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations quartiles by WoS per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Publication PDF

Metrics

Cite this

GOST |

Cite this

GOST Copy

Liu H. et al. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro // mAbs. 2021. Vol. 13. No. 1.

GOST all authors (up to 50) Copy

Liu H., WEI P., Zhang Q., Chen Z., Aviszus K., DOWNING W., Peterson S., Reynoso L., Downey G., Frankel S. K., John K., Kappler J. W., Marrack P. C., Zhang G. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro // mAbs. 2021. Vol. 13. No. 1.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1080/19420862.2021.1919285

UR - https://doi.org/10.1080/19420862.2021.1919285

TI - 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro

T2 - mAbs

AU - Liu, Haolin

AU - WEI, PENGCHENG

AU - Chen, Zhongzhou

AU - Aviszus, Katja

AU - DOWNING, Walter

AU - Peterson, Shelley

AU - Reynoso, Lyndon

AU - Downey, Gregory P.

AU - Frankel, Stephen K.

AU - John, Kappler

AU - Marrack, Philippa C.

AU - Zhang, Gongyi

AU - Zhang, Qianqian

AU - Kappler, John W.

PY - 2021

DA - 2021/01/01 00:00:00

PB - Taylor & Francis

IS - 1

VL - 13

SN - 1942-0862

SN - 1942-0870

ER -

BibTex

Cite this

BibTex Copy

@article{2021_Liu,

author = {Haolin Liu and PENGCHENG WEI and Zhongzhou Chen and Katja Aviszus and Walter DOWNING and Shelley Peterson and Lyndon Reynoso and Gregory P. Downey and Stephen K. Frankel and Kappler John and Philippa C. Marrack and Gongyi Zhang and Qianqian Zhang and John W. Kappler},

title = {501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro},

journal = {mAbs},

year = {2021},

volume = {13},

publisher = {Taylor & Francis},

month = {jan},

url = {https://doi.org/10.1080/19420862.2021.1919285},

number = {1},

doi = {10.1080/19420862.2021.1919285}

}

Found error?

Publisher

Taylor & Francis

Journal

mAbs

Quartile SCImago

Quartile WOS

Impact factor

5.3

ISSN

19420862 (Print)
19420870 (Electronic)